

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)

2021 THIRD QUARTERLY REPORT

This announcement is made pursuant to Rule 13.09(2) and Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The following is the third quarterly report of WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) for financial year 2021 (the “**2021 Third Quarterly Report**”). The financial report therein is prepared in accordance with the PRC Accounting Standards for Business Enterprises or the International Financial Reporting Standards issued by the International Accounting Standards Board (the “**IFRSs**”) (as applicable) and has not been audited.

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, October 29, 2021

As of the date of this announcement, the Board of the Company comprises Dr. Ge Li, Mr. Edward Hu, Dr. Steve Qing Yang, Mr. Zhaohui Zhang and Dr. Ning Zhao as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Dr. Jiangnan Cai, Ms. Yan Liu, Mr. Dai Feng, Dr. Hetong Lou and Mr. Xiaotong Zhang as independent non-executive Directors.

* *For identification purpose only*

I. Important Notice

- 1.1 The Board, the Supervisory Committee and the Directors, the supervisors and the senior management of the Company warrant the truthfulness, accuracy and completeness of the contents of the 2021 Third Quarterly Report and that there are no false information, misleading statements or material omissions in the 2021 Third Quarterly Report, and shall assume several and joint legal responsibilities.
- 1.2 Ge Li, the person in charge of the Company, Ellis Bih-Hsin Chu, the chief financial officer and Jin Sun, the director of the accounting department (person in charge of accounting) warrant the truthfulness, accuracy and completeness of the financial statements contained in the 2021 Third Quarterly Report.
- 1.3 The 2021 Third Quarterly Report of the Company has not been audited.
- 1.4 Definitions

Definitions of frequently-used terms

“A Share(s)”	domestic shares of the Company, with a nominal value of RMB1.00 each, which are listed for trading on the Shanghai Stock Exchange and traded in RMB
“Board”	the board of directors of the Company
“CDMO”	Contract Development and Manufacturing Organization that provides customized development services of related products in addition to process development, formulation development, clinical trial drugs, manufacturing of chemically or biologically synthesized drug substances, manufacturing of intermediates, manufacturing of preparations (such as powder and injection), packaging and other services which are necessary for product manufacturing

“China” or “PRC”	the People’s Republic of China, which for the purpose of this quarterly report excludes the Hong Kong Special Administrative Region of the PRC, the Macao Special Administrative Region of the PRC and Taiwan
“clinical research”	part of medical research and health research, the purpose of which is to establish basic theories about human disease mechanisms, disease prevention and health promotion. Clinical research involves the study of doctor-patient interaction and diagnostic clinical information, data or patient group information
“clinical trial(s)”	systematical investigation of drugs conducted on human subjects (patients or healthy volunteers) to prove or reveal the function, adverse reactions and/or absorption, distribution, metabolism and excretion of the drug being investigated. The purpose of a clinical trial is to determine the therapeutic efficacy and safety of the drug
“CRDMO”	Contract Research Development and Manufacturing Organization
“CRO”	Contract Research Organization, an academic or commercial scientific organization which provides professional services for drug research of pharmaceutical enterprises and research and development organizations on a contract basis
“CTDMO”	Contract Testing Development and Manufacturing Organization
“DEL”	DNA-encoded library
“Director(s)”	the director(s) of the Company
“end of the Reporting Period”	September 30, 2021
“H Share(s)”	overseas listed foreign shares in the share capital of the Company with nominal value of RMB1.00 each, which are listed on the Stock Exchange

“IFRSs”	International Financial Reporting Standards issued by the International Accounting Standards Board
“IND filing”	filing for clinical trial of investigational new drug (IND), which is necessary before commencement of clinical trial
“precision medicine”	a new medical concept and medical model developed with the rapid advancement of genome sequencing technology and the cross-application of bioinformatics and big data science based on personalized medicine. Its essence is to analyze, identify, verify and apply biomarkers for large sample populations and specific disease types through omics technologies such as genomics and proteomics as well as cutting-edge medical technologies so as to accurately identify the cause of the disease and the target of treatment. It also accurately classifies different states and processes of a disease, and ultimately achieve the goal of personalized and precise treatment for the disease and specific patients, and improve the effectiveness of disease diagnosis, treatment and prevention
“PROTAC”	proteolysis targeting chimera
“Reporting Period”	the period from July 1, 2021 to September 30, 2021
“RMB” or “RMB million”	Renminbi yuan or million yuan
“Share(s)”	ordinary shares in the capital of the Company with a nominal value of RMB1.00 each, comprising A Shares and H Shares
“SMO”	Site Management Organization for clinical trials
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Supervisory Committee”	the supervisory committee of the Company
“U.S.”	the United States of America, its territories, its possession and all areas subject to its jurisdiction
“WIND”	WuXi IND service platform

II. Company Profile

The Company is a leading global pharmaceutical research and development services platform. Headquartered in Shanghai, China, the Company provides comprehensive and integrated platform services of discovery, development and manufacturing of small molecule drugs for over 5,640 customers (active customers) through 30 operation sites and branch offices across the globe, including in China, the U.S. and Europe. It provides global pharmaceutical companies with discovery, manufacturing and supporting services of new drugs through a platform covering the entire industry chain, and also offers certain testing services for medical devices as well as research, development and manufacturing services of precision medicine. As at the end of the Reporting Period, the Company had 33,305 employees, including 10,643 employees with a master's or higher degree and 1,184 employees with a Ph.D. or equivalent degree. A breakdown of our employees by function and by geography is set out below:

Position	China (including Hong Kong)	U.S.	Europe	Total
Research and development	26,630	931	139	27,700
Manufacturing	2,647	219	52	2,918
Sales	34	74	27	135
Management and administration	2,020	442	90	2,552
Total	<u>31,331</u>	<u>1,666</u>	<u>308</u>	<u>33,305</u>

To maintain the high service standards and industry leading expertise and continuously meet customers' demands, the Company will continue to recruit, train, promote, incentivize and retain talented individuals.

III. Major financial data

1. Major financial statement items and financial indicators

Unit: RMB

Item	For the Reporting Period	Year-over-year increase/decrease (%)	From the beginning	Year-over-year increase/decrease (%)
			of the year to the end of the Reporting Period	
Revenue	5,984,811,444.39	30.58	16,521,369,391.37	39.84
Net profit attributable to shareholders of the Company	887,126,326.88	36.23	3,562,226,936.53	50.41
Net profit attributable to shareholders of the Company after deducting non-recurring gain or loss items	979,098,052.70	87.28	3,106,202,684.32	87.81
Net cash flows from operating activities	Not applicable	Not applicable	3,180,775,809.35	31.33
Basic earnings per share (RMB/share)	0.30	30.43	1.22	41.86
Diluted earnings per share (RMB/share)	0.30	30.43	1.21	42.35
Weighted average return on net assets (%)	2.53	increased by 0.04 percentage points	10.23	decreased by 1.66 percentage points
				Increase/decrease of the end of the Reporting Period as compared to the end of the previous year (%)
	As at the end of the Reporting Period	As at the end of the previous year		
Total assets	53,173,933,656.92	46,291,165,698.55		14.87
Equity attributable to the shareholders of the Company	37,381,529,743.84	32,493,743,089.78		15.04

2. Non-recurring gain or loss items and amounts

Unit: RMB

Item	Amount for the Reporting Period	Amount for the period from the beginning of the year to the end of the Reporting Period	Description
Gain or loss on disposal of non-current assets (including the part offset by the provision for impairment of assets)	-3,467,906.51	-8,740,725.66	
Government grants included in profit or loss of the current period (except for those closely related to the Company's normal operation and which were granted on a recurring basis subject to certain amount or volume upon fulfilment of specific standards in compliance with the government policies and regulations)	27,367,339.96	141,968,823.34	
Gain or loss arising from changes in fair value of holding held-for-trading financial assets, held-for-trading financial liabilities, and investment income from disposal of held-for-trading financial assets, held-for-trading financial liabilities, and available-for-sale financial assets, except effective hedging business related to the Company's normal operations	-133,308,055.15	464,740,370.90	From January to September 2021, mainly include: gain of RMB1,299.1071 million from disposal of investment and gain of RMB551.6784 million from fair value changes in investment, and gain on disposal of held-for-trading financial assets of RMB82.9554 million, offset by loss of RMB1,468.8769 million from fair value change in convertible bonds, and loss of RMB0.1236 million from fair value changes in and settlement of non-hedging foreign currency forward contracts.
Other non-operating income and expenses other than the above items	-11,850,466.08	-17,887,635.45	
Less: Effect of income tax	-29,285,839.83	123,342,024.87	
Less: Impact on minority interests (after tax)	-1,522.13	714,556.05	
Total	-91,971,725.82	456,024,252.21	

Explanation on classifying the non-recurring profit or loss items listed in the “Explanatory Announcement on Information Disclosure for Companies Making Public Offering of Securities No. 1 — Non-recurring Profit or Loss” as recurring profit or loss items

Applicable Not applicable

3. Significant changes in major financial statement items and financial indicators of the Company and the reasons thereof

Applicable Not applicable

Item	Change for the Reporting Period (%)	Change for the period from the beginning of the year to the Reporting Period (%)	Main reasons
Revenue	30.58	39.84	Please refer to the note below for details.
Net profit attributable to shareholders of the Company	36.23	50.41	It was mainly due to significant growth in operating profit resulting from higher capacity utilization and operating efficiency.
Net profit attributable to shareholders of the Company after deducting non-recurring gain or loss items	87.28	87.81	It was mainly due to significant growth in operating profit resulting from higher capacity utilization and operating efficiency.
Net cash flows from operating activities	Not applicable	31.33	It was mainly due to the continued growth of main business, effective cost and payment control and improvement on turnover of trade receivables during the first three quarters of the year.
Basic earnings per share (RMB/share)	30.43	41.86	It was mainly due to the growth in net profit attributable to shareholders of the Company during the Reporting Period.
Diluted earnings per share (RMB/share)	30.43	42.35	It was mainly due to the growth in net profit attributable to shareholders of the Company during the Reporting Period.

Note: The percentage of change for the Reporting Period refers to the increase or decrease for the Reporting Period as compared with the corresponding period of the previous year. The percentage of change for the period from the beginning of the year to the Reporting Period refers to the increase or decrease for the period from January to September 2021 as compared with the corresponding period of the previous year.

Analysis note:

Revenue

The Group has been continuously developing its integrated and end-to-end capabilities across the businesses of research, development, manufacturing, testing and clinical trials, and has also been continuously implementing the CRDMO and CTDMO strategies of the Group, while managing the various operating segments of the Group on the basis of globalization. In order to provide more transparent and relevant accounting information in the financial report that is reflective of the current business management structure of the Group, the Company has decided to adjust the presentation of its operating segments. The adjustment only affects the presentation of segmental information in the notes to the financial report of the Company and does not affect the data of the financial statements of the Company such as its total assets, total liabilities, net assets and net profits. The data for the corresponding period in 2020 have also been restated according to the adjusted presentation of segment reports with effect from the third quarter of 2021. For details, please refer to the relevant announcement of the Company dated October 29, 2021.

Unit: Million Currency: RMB

Operating segments	Third quarter of 2021	Third quarter of 2020	Change (%)	First three quarters of 2021	First three quarters of 2020	Change (%)
Chemistry business (WuXi Chemistry)	3,651.4003	2,740.0229	33.3	10,077.1857	6,831.8211	47.5
Testing business (WuXi Testing)	1,227.2706	893.2748	37.4	3,334.5108	2,317.7453	43.9
Biology business (WuXi Biology)	504.1027	411.7287	22.4	1,424.3277	1,069.7068	33.2
Cell and gene therapy CTDMO business (WuXi ATU)	282.5219	246.2231	14.7	735.9310	776.3884	-5.2
Domestic Discovery Service Unit (WuXi DDSU)	311.0532	281.5123	10.5	931.7960	800.2152	16.4

In the third quarter of 2021, our revenue grew by 30.6% year-over-year (YoY) to RMB5,984.8114 million due primarily to the following:

- (1) Our chemistry business (WuXi Chemistry) realized revenue of RMB3,651.4003 million, representing a YoY growth of 33.3% from RMB2,740.0229 million. The revenue from small molecule drug discovery services was RMB1,616.0634 million, representing a YoY growth of 37.1%. The revenue from CDMO services was RMB2,035.3369 million, representing a YoY growth of 31.5%. By fully taking advantage of its competitiveness in R&D, the Company continued to execute our strategy of “follow the molecule”. With respect to small molecule drug discovery services, the Company completed approximately 200,000 units of compound synthesis from January to September 2021, which facilitated the early-stage small molecule new drug research of customers. It also served as an important source of the downstream business units of the Company. By establishing close collaborative relationships with our customers during the drug discovery stage and pre-clinical stage, we are able to seek opportunities for new projects from late clinical stage to the commercialization stage, facilitating sustainable and rapid growth in revenue from our CRDMO services. During the Reporting Period, the Company provided CDMO services for 1,548 new drug molecules, including 47 molecules in phase III clinical trials, 235 molecules in phase II clinical trials, 1,229 molecules in phase I clinical trials and pre-clinical stage, and 37 molecules approved for commercialization. During the Reporting Period, the Company also completed the acquisition of the production facilities in Couvet, Switzerland which began to be consolidated in July this year.

- (2) Our testing business (WuXi Testing) realized revenue of RMB1,227.2706 million, representing a YoY growth of 37.4% from RMB893.2748 million. The revenue from laboratory analysis and testing services was RMB808.6688 million, representing a YoY growth of 39.8%. The revenue from clinical CRO and SMO was RMB418.6018 million, representing a YoY growth of 33.0%. Revenue from drug analysis and testing services (excluding medical devices testing) saw significant YoY growth of 46.7%. In respect of drug analysis and testing services, the Company provided customers with a series of services such as drug metabolism and pharmacokinetics, toxicology, bioanalysis. The Company continued to leverage its integrated platform. Through its WIND service platform, the Company integrated pre-clinical pharmacodynamics, drug metabolism, safety evaluation, filing material preparation and submission to provide customers with integrated services covering new drug research and development and global filing, which accelerated the new drug research and development of customers. From January to September 2021, approximately 123 service projects were obtained through the WIND platform with an average project sum of 1.1 million to 1.5 million U.S. dollars. Compared with the corresponding period of the previous year, revenue from the toxicology business of the Company maintained a strong growth momentum with a YoY growth of 72% during the Reporting Period. The Company has maintained and strengthened its leading position in the toxicology industry in China. In respect of clinical CRO services, the Company provided clinical trial development services for over 200 projects from January to September 2021, which helped customers obtain approval for 14 clinical research applications and complete 5 new drug applications. The Company continued to improve the development of its business. The data statistics and analysis business of the Company has been developing rapidly. In respect of SMO services, the Company continued to expand rapidly. As at the end of the third quarter of 2021, the SMO team had about 4,500 staff members, representing a YoY growth of 42%, across approximately 1,000 hospitals in 153 cities in China.

- (3) Our biology business (WuXi Biology) realized revenue of RMB504.1027 million, representing a YoY growth of 22.4% from RMB411.7287 million. The DEL of the Company has a leading position in the market. As at the end of the third quarter of 2021, the Company had over 90 billion DEL compound molecules, 6,000 molecular scaffolds and 35,000 molecular building blocks. During the Reporting Period, the Company further optimized its resource allocation. The Company integrated its DEL, protein production and protein structure-based drug discovery platform to develop a competitive integrated target-to-hit compound discovery platform to facilitate the early-stage small molecule new drug research of customers. In addition, our biology business focuses on developing new modalities, including oligonucleotide, cancer vaccines, PROTAC, vector platforms and innovative drug delivery systems. From January to September 2021, revenue from new modalities and biologic drugs under our biology business recorded a YoY growth of 56%, and its percentage in revenue from biology business increased from 10.4% as at the end of 2020 to 13.3% as at the end of the third quarter of 2021.
- (4) Our cell and gene therapy CTDMO business (WuXi ATU) realized revenue of RMB282.5219 million, representing a YoY growth of 14.7% from RMB246.2231 million. Our cell and gene therapy CTDMO business in China recorded rapid YoY growth of 223% in revenue, which partially offset the negative impact of the decline of such business in the U.S. In respect of service platform, the Company further improved the development and production for cell and gene therapy products. The Company provided testing services for 326 projects and development and manufacturing services for 61 projects, including 45 projects in pre-clinical stage and phase I clinical trials, six projects in phase II clinical trials and 10 projects in phase III clinical trials.
- (5) Our Domestic Discovery Service Unit (WuXi DDSU) realized revenue of RMB311.0532 million, representing a YoY growth of 10.5% from RMB281.5123 million. During the Reporting Period, the Company helped customers complete IND filing process for 16 projects and obtain 12 clinical trial approvals. As at the end of the third quarter of 2021, the Company had completed IND filing for 136 projects and obtained clinical trial approvals for 103 projects. In addition, new drug application for 1 project was in progress, and there were 1 project, 14 projects and 73 projects in Phase III, Phase II and Phase I clinical trials, respectively. Among the 136 projects that INDs were filed or currently in clinical stage, more than 70% were among the top 3 in terms of clinical trial progress for similar drug candidates in China. Upon the commercialization of customers' products, the Company will share the revenue from customers at an agreed percentage when their products are sold, in accordance with the relevant customer agreements.

IV. Information about shareholders

1. Total number of ordinary shareholders, total number of preference shareholders with voting rights restored and shareholdings of the top 10 shareholders as at the end of the Reporting Period

Unit: share

Total number of ordinary shareholders as at the end of the Reporting Period	187,267	Total number of preference shareholders with voting rights restored at the end of the Reporting Period (if any)	Nil
---	---------	---	-----

Shareholdings of top 10 Shareholders

Full name of shareholder	Nature of shareholders	Number of Shares held as at the end of the Reporting Period	Percentage (%)	Number of Shares subject to trading restrictions	Pledged, marked or frozen Shares Status	Number
HKSCC NOMINEES LIMITED (Note 1)	Overseas legal entity	389,105,235	13.1773	0	Unknown	0
Hong Kong Securities Clearing Company Limited (Note 2)	Overseas legal entity	194,895,553	6.6003	0	Unknown	0
G&C VI Limited	Overseas legal entity	190,512,000	6.4518	0	Nil	0
SUMMER BLOOM INVESTMENTS (I) PTE. LTD.	Overseas legal entity	159,160,073	5.3901	0	Nil	0
G&C IV Hong Kong Limited	Overseas legal entity	139,319,309	4.7181	0	Nil	0
G&C V Limited	Overseas legal entity	97,349,515	3.2968	0	Nil	0
Beijing Zhongmin Yinfu Investment Management Co., Ltd. — Jiaxing Yuxiang Investment Partnership (Limited Partnership)	Other	87,074,568	2.9488	0	Nil	0
G&C VII Limited	Overseas legal entity	50,415,120	1.7073	0	Nil	0
Shanghai Houshen Investment Center (Limited Partnership)	Other	45,735,228	1.5489	0	Nil	0
Industrial and Commercial Bank of China Limited — China-Europe Medical and Health Hybrid Securities Investment Fund (中國工商銀行股份有限公司 — 中歐醫療健康混合型證券投資基金)	Other	40,909,369	1.3854	0	Nil	0

Shareholdings of top 10 holders of Shares not subject to trading restrictions

Name of shareholder	Class and number of Shares		
	Number of Shares not subject to trading restrictions	Class	Number
HKSCC NOMINEES LIMITED (<i>Note 1</i>)	389,105,235	Overseas-listed foreign shares	389,105,235
Hong Kong Securities Clearing Company Limited (<i>Note 2</i>)	194,895,553	RMB-denominated ordinary shares	194,895,553
G&C VI Limited	190,512,000	RMB-denominated ordinary shares	190,512,000
SUMMER BLOOM INVESTMENTS (I) PTE. LTD.	159,160,073	RMB-denominated ordinary shares	159,160,073
G&C IV Hong Kong Limited	139,319,309	RMB-denominated ordinary shares	139,319,309
G&C V Limited	97,349,515	RMB-denominated ordinary shares	97,349,515
Beijing Zhongmin Yinfu Investment Management Co., Ltd. — Jiaxing Yuxiang Investment Partnership (Limited Partnership)	87,074,568	RMB-denominated ordinary shares	87,074,568
G&C VII Limited	50,415,120	RMB-denominated ordinary shares	50,415,120
Shanghai Houshen Investment Center (Limited Partnership)	45,735,228	RMB-denominated ordinary shares	45,735,228
Industrial and Commercial Bank of China Limited — China-Europe Medical and Health Hybrid Securities Investment Fund (中國工商銀行股份有限公司 — 中歐醫療健康混合型證券投資基金)	40,909,369	RMB-denominated ordinary shares	40,909,369
Description of connected relationships or concerted actions of the above shareholders	G&C VI Limited, G&C IV Hong Kong Limited, G&C V Limited, G&C VII Limited, and Shanghai Houshen Investment Center (Limited Partnership) being part of the top 10 shareholders of the Company, are under the control of Ge Li.		
The participation of top 10 shareholders and top 10 shareholders holding Shares not subject to trading restrictions in financing, financial notes and financial institution backed securities business (if any)	Not applicable		

Note 1: HKSCC NOMINEES LIMITED holds shares on behalf of its multiple clients.

Note 2: Hong Kong Securities Clearing Company Limited is the nominee holder of the RMB denominated ordinary shares under the Shanghai-Hong Kong Stock Connect.

V. Other reminders

Other important information about the Company's operating conditions during the Reporting Period that investors need to be reminded of and pay attention to.

Applicable Not applicable

VI. Quarterly financial statements

1. Type of auditor's opinion

Applicable Not applicable

2. Financial statements

Consolidated Balance Sheet

As at September 30, 2021

Prepared by: WuXi AppTec Co., Ltd.

Unit: RMB Type of audit: Unaudited

Item	As at September 30, 2021	As at December 31, 2020
Current Assets:		
Bank balances and cash	8,366,496,069.53	10,237,170,216.15
Financial assets held for trading	2,190,734,753.82	4,617,724,684.99
Derivative financial assets	191,065,636.17	562,824,032.02
Note receivables	6,228,009.21	2,500,000.00
Trade receivables	4,502,590,254.42	3,664,789,832.59
Prepayments	281,292,430.39	175,731,609.47
Other receivables	75,881,952.43	33,916,022.02
Including: Interest receivables	49,709.59	2,247,270.86
Dividend receivables	—	—
Inventories	4,520,353,214.50	2,685,858,968.33
Contract assets	761,692,369.50	541,952,792.04
Other current assets	646,945,292.40	536,871,759.36
Total Current Assets	21,543,279,982.37	23,059,339,916.97

Item	As at September 30, 2021	As at December 31, 2020
Non-current Assets:		
Long-term equity investments	802,476,175.85	764,832,343.04
Other non-current financial assets	8,905,535,833.00	6,717,206,517.57
Fixed assets	7,434,261,756.96	5,710,067,919.14
Construction in progress	5,435,509,106.68	3,086,116,115.11
Productive biological assets	651,566,000.00	418,869,000.00
Right-of-use assets	1,101,449,739.99	1,107,519,333.99
Intangible assets	1,595,390,119.07	997,663,520.66
Goodwill	1,939,750,861.82	1,391,759,037.62
Long-term deferred expenditures	1,328,585,029.83	1,357,522,536.54
Deferred tax assets	293,111,849.17	300,900,804.32
Other non-current assets	2,143,017,202.18	1,379,368,653.59
Total Non-current Assets	31,630,653,674.55	23,231,825,781.58
Total Assets	53,173,933,656.92	46,291,165,698.55
Current Liabilities:		
Short-term borrowings	2,296,776,950.00	1,230,010,900.00
Financial liabilities held for trading	—	16,507,997.00
Derivative financial liabilities	16,474,045.46	858,612.35
Note payables	—	11,652,388.59
Trade payables	1,508,348,437.03	929,731,152.30
Contract liabilities	2,548,343,363.97	1,580,979,702.23
Payroll payables	1,338,651,143.94	1,139,557,476.59
Tax payables	468,849,750.83	378,656,659.08
Other payables	2,789,215,256.52	2,454,568,919.68
Including: Interest payables	1,209,133.21	847,997.93
Dividend payables	—	—
Non-current liabilities due within one year	172,514,566.59	177,436,405.49
Other current liabilities	—	384,653.23
Total Current Liabilities	11,139,173,514.34	7,920,344,866.54

Item	As at September 30, 2021	As at December 31, 2020
Non-current Liabilities:		
Bond payables	755,619,487.21	1,819,028,586.29
Including: Preference shares	—	—
Perpetual bonds	—	—
Rental liabilities	1,094,243,189.99	1,067,102,918.35
Deferred income	681,088,422.26	682,034,864.55
Deferred tax liabilities	293,699,924.99	282,986,772.94
Other non-current liabilities	1,570,820,131.46	1,801,176,381.16
Total Non-current Liabilities	4,395,471,155.91	5,652,329,523.29
Total Liabilities	15,534,644,670.25	13,572,674,389.83
Owners' Equity (or Shareholders' Equity):		
Paid-in capital (or share capital)	2,952,843,602.00	2,441,684,821.00
Capital reserve	25,323,124,899.09	22,678,175,352.71
Less: Treasury shares	1,737,823,700.87	1,189,921,407.47
Other comprehensive income	-156,123,969.48	236,942,350.53
Special reserve	—	—
Surplus reserve	238,896,564.09	238,896,564.09
Undistributed profit	10,760,612,349.01	8,087,965,408.92
Total Equity (or Shareholders' Equity) attributable to owners of the Company	37,381,529,743.84	32,493,743,089.78
Minority interests	257,759,242.83	224,748,218.94
Total Owners' Equity (or Shareholders' Equity)	37,639,288,986.67	32,718,491,308.72
Total Liabilities and Owners' Equity (or Shareholders' Equity)	53,173,933,656.92	46,291,165,698.55

Legal Representative:	Ge Li
Chief Financial Officer:	Ellis Bih-Hsin Chu
Director of the Accounting Department:	Jin Sun

Consolidated Income Statement

January to September 2021

Prepared by: WuXi AppTec Co., Ltd

Unit: RMB Type of audit: Unaudited

Item	First three quarters of 2021 (January – September)	First three quarters of 2020 (January – September)
I. Total revenue	16,521,369,391.37	11,814,802,985.22
Including: Revenue	16,521,369,391.37	11,814,802,985.22
II. Total cost	13,137,666,500.63	9,915,155,578.94
Including: Cost	10,410,754,419.19	7,374,781,534.27
Taxes and surcharges	33,881,553.53	23,489,740.63
Selling expenses	497,157,806.57	410,788,005.00
Administrative expenses	1,505,726,229.89	1,304,332,457.93
Research and development expenses	644,205,887.55	475,160,617.75
Finance expenses	45,940,603.90	326,603,223.36
Including: Interest expense	52,374,900.98	117,765,221.50
Interest income	144,266,882.07	42,212,862.68
Add: Other income	141,829,750.60	126,963,559.87
Investment gains (“-” indicating loss)	1,374,368,868.83	411,239,174.22
Including: Gains from investments in associates and joint ventures	-3,628,628.90	-90,684,351.77
Gains from changes in fair value (“-” indicating loss)	-547,860,299.26	312,090,742.03
Credit impairment losses (“-” indicating loss)	-23,159,137.74	-11,513,281.88
Assets impairment losses (“-” indicating loss)	-19,721,174.11	-10,173,426.54
Gains on assets disposal (“-” indicating loss)	-6,848,946.32	-4,566,306.12
III. Operating profit (“-” indicating loss)	4,302,311,952.74	2,723,687,867.86
Add: Non-operating income	6,507,568.77	3,087,147.88
Less: Non-operating expenses	26,147,910.86	18,675,386.55
IV. Total profit (“-” indicating total loss)	4,282,671,610.65	2,708,099,629.19
Less: Income tax expenses	694,427,828.13	320,994,194.03

Item	First three quarters of 2021 (January – September)	First three quarters of 2020 (January – September)
V. Net profit (“-” indicating net loss)	3,588,243,782.52	2,387,105,435.16
(I) Classified by continuity of operations		
1. Net profit from continuing operations (“-” indicating net loss)	3,588,243,782.52	2,387,105,435.16
2. Net profit from discontinued operations (“-” indicating net loss)	—	—
(II) Classified by ownership		
1. Net profit attributable to shareholders of the Company (“-” indicating net loss)	3,562,226,936.53	2,368,356,528.79
2. Profit attributable to minority shareholders (“-” indicating net loss)	26,016,845.99	18,748,906.37
VI. Other comprehensive income, net of tax	-396,270,807.97	43,504,321.35
(I) Other comprehensive income attributable to owners of the Company, net of tax	-393,066,320.01	41,648,470.00
1. Other comprehensive income that will not be reclassified to profit or loss	—	—
2. Other comprehensive income that will be reclassified to profit or loss	-393,066,320.01	41,648,470.00
(1) Other comprehensive income that will be transferred to profit or loss accounted for using equity method	—	—
(2) Changes in fair value of other debt investments	—	—
(3) Financial assets reclassified to other comprehensive income	—	—
(4) Credit impairment allowance of other debt investments	—	—
(5) Cash flow hedging reserve	-335,476,361.54	123,109,973.33
(6) Exchange difference on translation of foreign financial statements	-57,589,958.47	-81,461,503.33
(7) Others	—	—

Item	First three quarters of 2021 (January – September)	First three quarters of 2020 (January – September)
(II) Other comprehensive income attributable to minority shareholders, net of tax	-3,204,487.96	1,855,851.35
VII. Total comprehensive income	3,191,972,974.55	2,430,609,756.51
(I) Total comprehensive income attributable to owners of the Company	3,169,160,616.52	2,410,004,998.79
(II) Total comprehensive income attributable to minority shareholders	22,812,358.03	20,604,757.72
VIII. Earnings per share:		
(I) Basic earnings per share (RMB per share)	1.22	0.86
(II) Diluted earnings per share (RMB per share)	1.21	0.85

For the business combination involving enterprises under common control during the Reporting Period, realised net profit of the merged parties before the merger was nil (corresponding period of the previous year: nil).

Legal Representative:	Ge Li
Chief Financial Officer:	Ellis Bih-Hsin Chu
Director of the Accounting Department:	Jin Sun

Consolidated Statement of Cash Flows

January to September 2021

Prepared by: WuXi AppTec Co., Ltd.

Unit: RMB Type of audit: Unaudited

Item	First three quarters of 2021 (January – September)	First three quarters of 2020 (January – September)
I. Cash flow from operating activities:		
Cash received from sale of goods or rendering of services	16,823,642,634.30	11,734,779,320.85
Refunds of taxes and surcharges	567,694,786.51	383,550,855.93
Cash received relating to other operating activities	495,326,757.35	513,179,609.32
Sub-total of cash inflow from operating activities	17,886,664,178.16	12,631,509,786.10
Cash paid for purchasing goods and receiving services	7,583,830,606.03	5,084,323,959.27
Cash paid to and on behalf of employees	5,385,637,870.15	3,896,908,463.95
Payments of taxes and surcharges	697,993,885.70	485,276,529.31
Cash paid relating to other operating activities	1,038,426,006.93	743,095,965.44
Sub-total of cash outflow from operating activities	14,705,888,368.81	10,209,604,917.97
Net cash flow generated from operating activities	3,180,775,809.35	2,421,904,868.13
II. Cash flow from investing activities:		
Cash received from disposal of investments	3,119,237,661.99	496,960,832.78
Cash received from return on investments	105,273,599.29	64,407,612.14
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	3,114,416.24	6,121,167.71
Net cash received from disposal of subsidiaries and other business entities	—	—
Cash received relating to other investing activities	—	—
Sub-total of cash inflow from investing activities	3,227,625,677.52	567,489,612.63
Cash paid to acquire fixed assets, intangible assets and other long-term assets	4,830,368,492.06	1,920,021,281.00
Cash paid to acquire investments	1,812,320,451.48	3,171,932,989.21
Net cash paid to acquire subsidiaries and other business entities	857,689,819.74	41,945,756.27
Cash paid relating to other investing activities	—	—
Sub-total of cash outflow from investing activities	7,500,378,763.28	5,133,900,026.48
Net cash flow from investing activities	-4,272,753,085.76	-4,566,410,413.85

Item	First three quarters of 2021 (January – September)	First three quarters of 2020 (January – September)
III. Cash flow from financing activities:		
Cash received from capital contributions:	90,644,107.94	13,162,166,778.45
Including: Cash received from capital contribution by minority shareholders of subsidiaries	—	113,450,831.77
Cash received from borrowings	2,279,299,450.00	1,688,382,744.44
Cash received relating to other financing activities	—	—
Sub-total of cash inflow from financing activities	2,369,943,557.94	14,850,549,522.89
Cash repayments of borrowings	1,209,543,500.00	2,720,608,396.56
Cash payments for distribution of dividends, profits or interest expenses	907,880,921.69	619,764,277.93
Including: Dividends and profits paid by subsidiaries to minority shareholders	3,400,000.00	—
Cash paid relating to other financing activities	1,853,665,355.30	1,266,122,839.90
Sub-total of cash outflow from financing activities	3,971,089,776.99	4,606,495,514.39
Net cash flow generated from financing activities	-1,601,146,219.05	10,244,054,008.50
IV. Effect of fluctuations in exchange rates on cash and cash equivalents	-32,290,311.06	-23,181,616.30
V. Net increase in cash and cash equivalents	-2,725,413,806.52	8,076,366,846.48
Add: Balance of cash and cash equivalents at the beginning of the period	10,228,057,054.30	5,223,292,858.56
VI. Balance of cash and cash equivalents at the end of the period	7,502,643,247.78	13,299,659,705.04

Legal Representative:	Ge Li
Chief Financial Officer:	Ellis Bih-Hsin Chu
Director of the Accounting Department:	Jin Sun

3. Adjustments on the financial statements at the beginning of the first year of adopting new leasing standards since 2021

Applicable Not applicable

4. Quarterly condensed consolidated financial statements prepared in accordance with IFRSs

Consolidated Statement of Profit or Loss and Other Comprehensive Income
January to September 2021

Prepared by: WuXi AppTec Co., Ltd.

	Unit: RMB'000		Type of audit: Unaudited	
	Third quarter of 2021 (July – September)	Third quarter of 2020 (July – September)	First three quarters of 2021 (January – September)	First three quarters of 2020 (January – September)
Revenue	5,984,811	4,583,369	16,521,369	11,814,803
Cost of services	(3,784,733)	(2,818,740)	(10,437,564)	(7,391,589)
Gross profit	2,200,078	1,764,629	6,083,805	4,423,214
Other income	80,575	62,642	286,652	190,614
Other gains and losses	(24,265)	(156,347)	716,338	565,456
Impairment losses under expected credit losses ("ECL") model, net of reversal	(1,515)	(3,431)	(23,159)	(11,513)
Selling and marketing expenses	(141,899)	(136,285)	(497,158)	(410,788)
Administrative expenses	(543,060)	(495,804)	(1,538,336)	(1,325,061)
Research and development expenses	(239,775)	(141,722)	(644,206)	(475,161)
Operating profit	1,330,139	893,682	4,383,936	2,956,761
Share of (loss) profits of associates	(201,662)	(58,080)	15,624	(75,993)
Share of profits (loss) of joint ventures	3,041	(2,284)	(19,252)	(14,692)
Finance costs	(28,781)	(47,180)	(97,636)	(157,977)
Profit before tax	1,102,737	786,138	4,282,672	2,708,099
Income tax expense	(206,686)	(126,510)	(694,428)	(320,994)
Profit for the period	896,051	659,628	3,588,244	2,387,105

	Third quarter of 2021 (July – September)	Third quarter of 2020 (July – September)	First three quarters of 2021 (January – September)	First three quarters of 2020 (January – September)
Other comprehensive income (expense) for the period				
<i>Items that may be reclassified subsequently to profit or loss:</i>				
Exchange differences on translation of financial statements of foreign operations	13,288	(121,070)	(58,251)	(80,530)
Fair value (losses) gain on hedging instrument designated in cash flow hedges	(132,417)	116,670	(338,020)	124,034
Other comprehensive (expense) income for the period, net of income tax	(119,129)	(4,400)	(396,271)	43,504
Total comprehensive income for the period	776,922	655,228	3,191,973	2,430,609
Profit for the period attributable to:				
Owners of the Company	887,126	651,201	3,562,227	2,368,357
Non-controlling interests	8,925	8,427	26,017	18,748
	896,051	659,628	3,588,244	2,387,105
Total comprehensive income for the period attributable to:				
Owners of the Company	769,156	644,897	3,169,161	2,410,005
Non-controlling interests	7,766	10,331	22,812	20,604
	776,922	655,228	3,191,973	2,430,609
Earnings per share (expressed in RMB per share)				
– Basic	0.30	0.23	1.22	0.86
– Diluted	0.30	0.23	1.21	0.85

Consolidated Statement of Financial Position

As at September 30, 2021

Prepared by: WuXi AppTec Co., Ltd.

Unit: RMB'000 Type of audit: Unaudited

	As at September 30, 2021	As at December 31, 2020
Non-current Assets		
Property, plant and equipment	14,183,056	10,137,062
Right of use assets	1,803,111	1,519,864
Goodwill	1,939,751	1,391,759
Other intangible assets	893,729	585,319
Interest in associates	763,846	712,337
Interest in joint ventures	38,630	52,496
Deferred tax assets	293,112	300,901
Financial assets at fair value through profit or loss (“FVTPL”)	8,905,536	6,717,207
Other non-current assets	2,156,767	1,395,594
Biological assets	651,566	418,869
Amount due from related parties	1,550	419
	31,630,654	23,231,827
Total Non-current Assets		
Current Assets		
Inventories	3,494,448	1,933,826
Contract costs	448,195	250,345
Biological assets	577,710	501,688
Amounts due from related parties	18,831	56,885
Trade and other receivables	5,493,882	4,337,866
Contract assets	761,692	541,953
Income tax recoverable	225	19,057
Financial assets at FVTPL	2,190,735	4,617,725
Derivative financial instruments	191,066	562,824
Pledged bank deposits	863,853	9,113
Bank balances and cash	7,502,643	10,228,057
	21,543,280	23,059,339
Total Current Assets		
	53,173,934	46,291,166
Total Assets		

	As at September 30, 2021	As at December 31, 2020
Current Liabilities		
Trade and other payables	5,660,537	4,550,334
Amounts due to related parties	12,925	23,845
Derivative financial instruments	16,474	859
Contract liabilities	2,548,343	1,580,980
Borrowings	2,296,777	1,230,011
Lease liabilities	172,515	177,436
Income tax payables	431,603	340,371
Financial liabilities at FVTPL	—	16,508
	<hr/>	<hr/>
Total Current Liabilities	11,139,174	7,920,344
	<hr/>	<hr/>
Non-current Liabilities		
Deferred tax liabilities	293,700	282,987
Deferred income	681,088	682,035
Convertible bonds-debt component	755,619	1,819,029
Convertible bonds-derivative component	1,388,929	1,582,060
Lease liabilities	1,094,243	1,067,103
Other long-term liabilities	181,892	219,117
	<hr/>	<hr/>
Total Non-current Liabilities	4,395,471	5,652,331
	<hr/>	<hr/>
Total Liabilities	15,534,645	13,572,675
	<hr/>	<hr/>
Equity		
Share capital	2,952,844	2,441,685
Reserves	34,428,686	30,052,058
	<hr/>	<hr/>
Equity attributable to owners of the Company	37,381,530	32,493,743
Non-controlling interests	257,759	224,748
	<hr/>	<hr/>
Total Equity	<u>37,639,289</u>	<u>32,718,491</u>

Consolidated Statement of Cash Flows

January to September 2021

Prepared by: WuXi AppTec Co., Ltd.

Unit: RMB'000 Type of audit: Unaudited

	First three quarters of 2021 (January – September)	First three quarters of 2020 (January – September)
Net cash from operating activities	3,069,256	2,354,841
Net cash used in investing activities		
Interests received	86,617	35,390
Proceeds from disposal of financial assets at FVTPL	3,909,223	496,961
Purchase of financial assets at FVTPL	(1,751,582)	(2,517,416)
Proceeds from disposal of property, plant and equipment	2,255	6,086
Proceeds from disposal of other intangible assets	858	35
Purchase of other non-current assets	(700,000)	(500,000)
Acquisition of interests in associates/ investment in associates	(49,646)	(100,816)
Acquisition of interests in joint ventures/ investment in joint ventures	—	(26,667)
Purchase of property, plant and equipment	(4,696,616)	(1,883,532)
(Payments) return of rental deposits	(17,578)	3,655
Purchase of other intangible assets	(2,819)	(36,489)
Purchase of biological assets	(130,934)	—
Withdrawal (placement) of pledged bank deposits	239	(2,807)
Net cash outflow on acquisition of subsidiaries	(857,690)	(41,946)
Dividends received from associates	11,222	2,075
Dividends received from financial assets at FVTPL	4,069	62,333
Government grants and subsidies received relating to assets	42,240	30,825
Payment for forward contracts	(11,092)	(27,033)
	(4,161,234)	(4,499,346)

	First three quarters of 2021 (January – September)	First three quarters of 2020 (January – September)
Net cash (used in) from financing activities		
Payment of dividends	(892,980)	(556,430)
New borrowings raised	2,279,299	1,688,383
Repayment of borrowings	(1,209,543)	(2,720,608)
Acquisition of partial interest of a subsidiary from non-controlling shareholders	(13,621)	(462,176)
Proceeds from placing of H Shares	—	6,564,329
Proceeds from non-public A Shares issuance	—	6,465,924
Contribution from non-controlling shareholders	—	113,451
Proceeds from issuance of restricted A Shares and exercise of share options	90,644	18,462
Interests paid	(14,901)	(63,334)
Repurchase and cancellation of restricted A Shares	(5,405)	(20,535)
Repayment of lease liabilities	(167,201)	(166,223)
Issue cost paid	(1,318)	(2,085)
Repurchase of H shares for share incentive scheme	(1,666,120)	(615,104)
	<u>(1,601,146)</u>	<u>10,244,054</u>
Net (decrease)increase in cash and cash equivalents	(2,693,124)	8,099,549
Cash and cash equivalents at the beginning of the period	10,228,057	5,223,293
Effects of exchange rate changes	(32,290)	(23,182)
	<u>7,502,643</u>	<u>13,299,660</u>
Cash and cash equivalents at the end of the period	7,502,643	13,299,660